55 summarised stories about Drug Discovery, each linking back to the original source. Browse all topics →
SiliconANGLE 6 days ago 28
Isomorphic Labs, an Alphabet spinoff developing an AI platform for drug discovery, is reportedly in talks to raise new funding. The reported target valuation is $40 billion to $50 billion. If the round closes, Isomorphic’s partnerships and development of IsoDDE would likely accelerate as investors fund the company’s work.
YouTube 6 days ago 48
Trevor Martin of Mammoth Biosciences describes how the company uses AI to search large protein spaces and engineer smaller CRISPR systems for genetic disease work. The discussion highlights the key proof hurdle: validating what actually survives contact with a human body. The result is a clearer focus on biological validation rather than AI alone solving everything.
The daily briefing
TLDRocket reads all relevant sources, removes duplicate coverage, and summarises the day in two minutes. Follow companies and topics for alerts, or get the briefing in Slack. Free, no spam, unsubscribe anytime.
TLDRocket
15 October 2026
The biggest story today isn’t a single model release—it’s the plumbing getting thicker, especially for agentic AI. Nebius says it has struck deals with early-stage UK AI labs as it expands its GPU data-centre and compute offering in the UK, building on a planned £1.7bn build-out and an expanding London hub. That push rhymes with Britain’s British Business Bank, which announced £180m across six AI and deeptech VC funds, including £55m into Intrepid Growth Partners’ AI-focused Fund I, and with Nvidia’s own UK signal: CEO Jensen Huang announced minority-stake plans in five startups—Boltz, Foresight, Hiverge, Prima Mente, and Riverlane.
Read the full briefing →